Natco Pharma, Arrow International launch first generic version of Revlimid in U.S. market

08 Mar 2022 Evaluate

Natco Pharma along with its marketing partner Arrow International (an affiliate of Teva Pharmaceutical Industries) has launched the first generic version of Revlimid (Lenalidomide capsules) in 5mg, lOmg, lSmg, and 25mg strengths in the U.S. market.

The above strengths of lenalidomide capsules are prescribed in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment. Natco and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

1426.90 23.85 (1.70%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.